Skip to main content
. 2012 Dec 20;15(3):269–278. doi: 10.1093/neuonc/nos301

Fig. 4.

Fig. 4.

Nongenotoxic activation of the p53 pathway by nutlin-3 downregulates ALKBH2 expression. (A) CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting. (B) Cell cycle profiles of CCF-STTG1 cells treated with either drug vehicle (DMSO) alone or 8 µM nutlin-3 for 24h were determined by Edu labeling and flow cytometry. Cells in each phase were calculated from the flow cytograms and expressed as percentage of the total cell population. (C) Western blotting of CCF-STTG1 cells treated with drug vehicle, 8 µM nutlin-3, 25 µM MG132, or both for 24h. (D) ALKBH2 mRNA levels determined by qRT-PCR in CCF-STTG1 cells treated with 0–8 µM nutlin-3 for 24h. (E) U87 and U251 cells were treated with drug vehicle or 8 µM nutlin-3 for 24h before cell lysates were collected for western blotting. (F) ALKBH2 mRNA levels determined by qRT-PCR in U87 and U251 cells treated with drug vehicle or 8 µM nutlin-3 for 24h.